Learn more about current happenings at Ergomed.
London, UK – 21 June 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, announces that it has issued 47,000 new ordinary shares of 1p each in the Company (‘New Ordinary Shares’). The New Ordinary Shares have been allotted pursuant to exercise of share options awarded to two individuals under the Ergomed plc Long Term Incentive Plan.
Application has been made to the London Stock Exchange for 47,000 Ordinary Shares to be admitted to trading on AIM (‘Admission’). It is expected that Admission will occur at 8:00 a.m. on 22 June 2018. The Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.
Following Admission, the Company’s enlarged issued share capital and total number of voting rights will be 44,858,602 Ordinary Shares.
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Olivia Manser email@example.com
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: https://ergomedplc.com